Status:
COMPLETED
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
Lead Sponsor:
Eyetech Pharmaceuticals
Collaborating Sponsors:
Pfizer
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
The purpose of this study is to compare the ability of different doses of pegaptanib sodium to safely and effectively minimize fluid leakage within the eye, thereby stabilizing or impriving vision in ...
Eligibility Criteria
Inclusion
- Subjects of either gender, aged 50 years or greater. Subfoveal choroidal neovascularization (CNV) due to AMD. Best corrected visual acuity in the study eye between 20/40 and 20/320.
Exclusion
- Any prior subfoveal thermal laser therapy.
Key Trial Info
Start Date :
May 1 2001
Trial Type :
INTERVENTIONAL
End Date :
October 1 2007
Estimated Enrollment :
540 Patients enrolled
Trial Details
Trial ID
NCT00321997
Start Date
May 1 2001
End Date
October 1 2007
Last Update
May 4 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.